Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MABSTER

Financiado

Cerrado

Monoclonal Antibodies with Binding Sensitive To Environmental Regulation

Snakebite envenoming is a Neglected Tropical Disease (NTD) that each year affects 2.5 million victims and kills >100,000, unless they are treated with antivenom. Conventional antivenoms, derived from immunized animals, inflict ser... ver más

31/12/2024

TECHNICAL UNIVERSI...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

DANMARKS TEKNISKE UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-12-31

ERC-2019-STG: ERC Starting Grant Scope:Objectives

I+D

Cerrada hace 6 años

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

TECHNICAL UNIVERSITY OF DENM...

1.50M€ | Lider

AUTOTECH ENGINEERING AGRUPAC...

531.47K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 62 meses Fecha Inicio: 2019-10-08
Fecha Fin: 2024-12-31

Líder del proyecto

DANMARKS TEKNISKE UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Snakebite envenoming is a Neglected Tropical Disease (NTD) that each year affects 2.5 million victims and kills >100,000, unless they are treated with antivenom. Conventional antivenoms, derived from immunized animals, inflict serum sickness and anaphylaxis in patients, and are costly to manufacture. Monoclonal human antibodies with special toxin-binding properties that are sensitive towards regulation by their microenvironment (e.g. pH), which may be discovered using phage display selection, may solve this issue, providing significant societal impact by enabling the development of cost-effective antivenoms to victims in low and middle-income countries. In this project, phage display selection, high-density peptide microarray technology, and antibody engineering techniques will in three scientific objectives be harnessed in the pursuit of developing novel methodologies for discovery of therapeutic human monoclonal antibodies that are recyclable (can neutralize more than one snake toxin per antibody), broadly cross-reactive (can neutralize different types of snake toxins), and that are both broadly cross-reactive and recyclable at the same time. This will open up for entirely new ways of designing biotherapeutics against complex indications, such snakebite envenoming, but also cancer, infectious, and parasitic diseases, where the targets can be elusive due to hyper-mutability. The ERC Starting Grant offers a unique opportunity to consolidate me as an international key scientific researcher in this field of antibody discovery and NTDs. I have already independently led a research group in this area for 2 years, I have in-depth experience with toxin-targeted antibody discovery (my dr.tech dissertation similar to the German habilitation will be submitted during fall 2018), and I am already involved in high level policy in the field of snakebite envenoming via my role as a scientific advisor for the World Health Organization.

Conecta tu I+D

Entra hoy

Forgot your password?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores